https://www.selleckchem.com/products/vy-3-135.html
Patients will be screened for circulating blood mutation detection at regular intervals. Patients for whom a rising circulating mutation is detected without tumour progression (up to N=20 will be randomised (11) between (1) Arm A no modification of therapy; and (2) Arm B palbociclib in combination with fulvestrant, a selective ER down-regulator. At tumour progression, an optional crossover will be offered to patients randomised in arm A. The coprimary endpoints are (1) Grade ≥3 haematological toxicities and their associations with ba
Aimer
Commentaire
Partagez
